Last reviewed · How we verify

NCT05374122

AI Guidance for Biopsy in Suspected Cholangiocarcinoma

Status unknown NA Last updated 6 March 2023
What this trial tests

NA trial testing DSOC with AI biopsy guidance in Neoplasms in 48 participants. Status unknown.

Timeline
1 May 2022
Primary endpoint
30 December 2023
1 May 2024

Quick facts

Lead sponsorInstituto Ecuatoriano de Enfermedades Digestivas
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposediagnostic
Enrollment48
Start date1 May 2022
Primary completion30 December 2023
Estimated completion1 May 2024
Sites1 location across Ecuador

Drugs / interventions tested

Conditions studied

Sponsor

Instituto Ecuatoriano de Enfermedades Digestivas — full company profile →

Who can join

Adults 18 to 99, any sex, with Neoplasms or Non-Neoplastic. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Digital single-operator cholangioscopy (DSOC) has emerged as a medical advance with an important role in the evaluation of indeterminate biliary lesions. This technique has demonstrated higher sensitivity in the guidance for tissue acquisition when compared with standard endoscopic retrograde cholangiopancreatography (ERCP). DSOC-guided biopsy is considered technically safe and successful for tissue collection. Hand in hand with the development of more precise diagnostic techniques, comes the implementation of artificial intelligence (AI) for diagnostic assessment. For the past decade, the role of artificial intelligence (AI) has been increasing at a rapid pace. In the biliary tract, different models have been proposed for the characterization of malignant features. Nevertheless, to date, the discrepancy between the visual impression of the operator and the histological results obtained by cholangioscopy still present, affecting the accuracy the diagnosis. Based on the above, the investigators aim to assess the diagnostic accuracy of AI for the guidance of tissue acquisition with DSOC compared to DSOC without AI for suspected cholangiocarcinoma. As a secondary aim, the investigators pursue to compare quality of AI-guided biopsies samples vs. DSOC biopsies without AI.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Understanding Liver and Digestive Diseases: A Paved Road to Improve Diagnosis, Management, and Treatment.
    Bergheim I, Cadranel JF, Chen JG, Ding WX, et al · · 2026 · PMID 41953857 · DOI 10.37349/edd.2026.1005110

Verify or expand the search:

Other recruiting trials for Neoplasms

Currently open trials in the same condition.

Other Instituto Ecuatoriano de Enfermedades Digestivas trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05374122.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing